Hypomagnesemia signals nonrecovery of renal function in AKI

NewsGuard 100/100 Score

By Ingrid Grasmo

Researchers have identified hypomagnesemia as a risk factor for nonrecovery of renal function among critically ill patients with acute kidney injury (AKI).

Hypomagnesemia, defined as a total serum magnesium concentration below 0.70 mmol/L, is a frequent electrolyte abnormality that occurs in over 12% of all hospitalized patients and 60-65% of those in intensive care.

Cassiana Mazon Fraga (Universidade do Extremo Sul Catarinense, Santa Catarina, Brazil) and colleagues investigated whether measuring daily magnesium serum levels among 232 patients admitted to an intensive care unit (ICU) could help identify those who fail to recover renal function.

In all, 118 patients developed AKI according to the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) criteria, 71 recovered from AKI, and 88 patients died.

The overall prevalence of hypomagnesemia among patients was 63%, with 97 of those admitted to the ICU already presenting with the condition. The average duration of hypomagnesemia during ICU stay was 3.1 days.

The prevalence of hypomagnesemia was similar between patients with and without AKI, at 47% and 62%, respectively, and the presence or absence of hypomagnesemia was not associated with AKI.

However, it was associated with the recovery of renal function, occurring in just 30% of patients who recovered renal function, defined as an absence of AKI by RIFLE criteria over a 48-hour period or at ICU discharge, compared with 70% of those who did not.

Multivariate analysis that took into account sepsis and RIFLE classification showed that hypomagnesemia was a significant risk factor for nonrecovery of renal function, with ICU mortality similar in patients with and without hypomagnesemia.

"Hypomagnesemia is an independent risk factor for non-recovery of renal function among AKI patients in the ICU," conclude the authors in Nephrology Dialysis Transplantation.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gene therapy and glycoside drugs offer new hope for polycystic kidney disease treatment